Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 141,200 shares, an increase of 27.7% from the December 31st total of 110,600 shares. Based on an average trading volume of 95,500 shares, the short-interest ratio is presently 1.5 days. Approximately 0.7% of the company’s shares are short sold.

Institutional Investors Weigh In On Aileron Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. KG&L Capital Management LLC acquired a new stake in Aileron Therapeutics during the 3rd quarter valued at approximately $46,000. Sigma Planning Corp lifted its position in shares of Aileron Therapeutics by 68.3% in the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after buying an additional 86,185 shares during the last quarter. Geode Capital Management LLC raised its stake in Aileron Therapeutics by 34.8% during the third quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after acquiring an additional 59,370 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new position in Aileron Therapeutics in the second quarter valued at approximately $4,925,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Price Performance

Aileron Therapeutics has a 52 week low of $1.61 and a 52 week high of $7.42. The stock’s 50-day simple moving average is $2.52 and its 200 day simple moving average is $2.80.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).